RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Transcode Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.70+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.53 (−88.84%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.63M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1199.77%
Fundamentals
- Net income
- -$42.83M
- EPS, diluted
- -$52.59
- Free cash flow
- -$19.52M
- Book value per share
- -$28.93
- Diluted shares
- 1M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$45.13M
Net income
-$42.83M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months